Kiniksa (KNSA) director Popovits exercises 2,799 RSUs and receives 12,158-share option grant

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc director Kimberly J. Popovits reported routine equity compensation transactions. On May 29, 2026, she exercised 2,799 Restricted Share Units into an equal number of Class A Ordinary Shares, bringing her direct Class A Ordinary Share holdings to 15,345 shares after the transaction.

On the same date, she received new awards of 2,026 Restricted Share Units and a share option for 12,158 Class A Ordinary Shares at an exercise price of $48.38 per share. The option vests in twelve substantially equal monthly installments starting from the May 29, 2026 grant date, and the RSUs vest in full on the earlier of the first anniversary of the grant or the next annual shareholder meeting.

Insider Trade Summary

2,799 shares exercised/converted

Mixed 4 txns

Insider Popovits Kimberly J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option	12,158	$0.00	--
Grant/Award	Restricted Share Units	2,026	$0.00	--
Exercise	Restricted Share Units	2,799	$0.00	--
Exercise	Class A Ordinary Share	2,799	$0.00	--

Holdings After Transaction: Share Option — 12,158 shares (Direct); Restricted Share Units — 2,026 shares (Direct); Class A Ordinary Share — 15,345 shares (Direct)

Footnotes (1)

1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

Key Figures

RSUs exercised into shares: 2,799 shares Shares held after transaction: 15,345 shares New RSU grant: 2,026 units +3 more

6 metrics

RSUs exercised into shares 2,799 shares Class A Ordinary Shares received on May 29, 2026

Shares held after transaction 15,345 shares Direct Class A Ordinary Share holdings post-transaction

New RSU grant 2,026 units Restricted Share Units granted May 29, 2026

New option grant size 12,158 shares Share option underlying Class A Ordinary Shares

Option exercise price $48.38 per share Share option granted May 29, 2026

Option expiration date May 28, 2036 Share option term end

Key Terms

Restricted Share Unit, share option, vests in their entirety, exercise or conversion of derivative security

4 terms

Restricted Share Unit financial

"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."

A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.

share option financial

"The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant."

vests in their entirety financial

"The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting."

exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/02/2026 - 04:51 PM Accepted by SEC EDGAR 06/02/2026 - 04:51 PM Learn about SEC filing dates

FAQ

What did Kiniksa (KNSA) director Kimberly J. Popovits report on this Form 4?

She reported routine equity compensation activity, including exercising 2,799 Restricted Share Units into Class A Ordinary Shares and receiving new grants of 2,026 RSUs plus a share option for 12,158 shares, all on May 29, 2026.

How many Kiniksa (KNSA) Class A Ordinary Shares does Kimberly J. Popovits hold after these transactions?

After exercising 2,799 Restricted Share Units into Class A Ordinary Shares, Kimberly J. Popovits directly holds 15,345 Class A Ordinary Shares. This figure reflects her direct ownership position immediately following the reported May 29, 2026 transactions.

What new Restricted Share Units did Kimberly J. Popovits receive from Kiniksa (KNSA)?

She received a grant of 2,026 Restricted Share Units, each representing a contingent right to one Class A Ordinary Share. These RSUs vest in full on the earlier of the first anniversary of the May 29, 2026 grant or the next annual shareholder meeting.

What are the terms of the new share option granted to Kimberly J. Popovits at Kiniksa (KNSA)?

She was granted a share option covering 12,158 Class A Ordinary Shares with an exercise price of $48.38 per share. The option vests in twelve substantially equal monthly installments following the May 29, 2026 grant date and expires on May 28, 2036.

Did Kimberly J. Popovits sell any Kiniksa (KNSA) shares in this Form 4 filing?

No sales were reported. The Form 4 shows an exercise of 2,799 Restricted Share Units into Class A Ordinary Shares and new grants of 2,026 RSUs and a 12,158-share option, all classified as acquisitions rather than dispositions.

How do the Restricted Share Units for Kiniksa (KNSA) described in this filing work?

Each Restricted Share Unit represents a contingent right to receive one Class A Ordinary Share. In this filing, some RSUs vested into 2,799 shares on May 29, 2026, while a new 2,026-unit grant will vest later based on time and the annual shareholder meeting schedule.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Popovits Kimberly J

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON W1J 7NJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	05/29/2026		M		2,799	A	(1)	15,345	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$48.38	05/29/2026		A		12,158		(2)	05/28/2036	Class A Ordinary Shares	12,158	$0	12,158	D
Restricted Share Units	(1)	05/29/2026		A		2,026		(3)	(3)	Class A Ordinary Shares	2,026	$0	2,026	D
Restricted Share Units	(1)	05/29/2026		M			2,799	(4)	(4)	Class A Ordinary Shares	2,799	$0	0	D

Explanation of Responses:

1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

2. The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

3. The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

4. The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

	/s/ Douglas Barry, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)